NYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free EW Stock Alerts $95.56 +0.41 (+0.43%) (As of 05:42 PM ET) Add Compare Share Share Today's Range$94.87▼$96.1250-Day Range$72.55▼$94.6852-Week Range$60.57▼$96.12Volume4.01 million shsAverage Volume4.08 million shsMarket Capitalization$57.46 billionP/E Ratio41.55Dividend YieldN/APrice Target$88.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Edwards Lifesciences alerts: Email Address Edwards Lifesciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside7.1% Downside$88.80 Price TargetShort InterestHealthy1.77% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.57Based on 12 Articles This WeekInsider TradingSelling Shares$16.45 M Sold Last QuarterProj. Earnings Growth12.32%From $2.76 to $3.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.37 out of 5 starsMedical Sector136th out of 938 stocksSurgical Appliances & Supplies Industry5th out of 17 stocks 2.3 Analyst's Opinion Consensus RatingEdwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 10 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $88.80, Edwards Lifesciences has a forecasted downside of 7.1% from its current price of $95.56.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.77% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently increased by 23.82%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEdwards Lifesciences has received a 54.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Catheters", "Mitral valve repair devices", and "Artificial heart valves" products. See details.Environmental SustainabilityThe Environmental Impact score for Edwards Lifesciences is -0.95. Previous Next 2.5 News and Social Media Coverage News SentimentEdwards Lifesciences has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Edwards Lifesciences this week, compared to 10 articles on an average week.Search InterestOnly 19 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows51 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 11% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,445,296.00 in company stock.Percentage Held by InsidersOnly 1.29% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 12.32% in the coming year, from $2.76 to $3.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 41.55, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.11.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 41.55, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 212.34.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 4.63. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 8.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Edwards Lifesciences Stock (NYSE:EW)Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Read More EW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EW Stock News HeadlinesMarch 17, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) VP Sells $156,030.70 in StockMarch 14, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) VP Sells $1,319,645.00 in StockMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 12, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) VP Sells $1,320,192.00 in StockMarch 28, 2024 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Rating Increased to Positive at OTR GlobalMarch 25, 2024 | finance.yahoo.comAre Medical Stocks Lagging Edwards Lifesciences (EW) This Year?March 23, 2024 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) PT Raised to $103.00 at Morgan StanleyMarch 22, 2024 | benzinga.comBehind the Scenes of Edwards Lifesciences's Latest Options TrendsMarch 28, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. March 20, 2024 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Downgraded by StockNews.com to "Hold"March 19, 2024 | finance.yahoo.comEdwards Lifesciences Stock Earns Relative Strength Rating Upgrade; Hits Key BenchmarkMarch 19, 2024 | finance.yahoo.comEdwards Lifesciences Corporation's (NYSE:EW) Intrinsic Value Is Potentially 17% Below Its Share PriceMarch 19, 2024 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Price Target Increased to $100.00 by Analysts at OppenheimerMarch 16, 2024 | finance.yahoo.comEW Apr 2024 100.000 callMarch 16, 2024 | finance.yahoo.comCAH Apr 2024 123.000 callMarch 14, 2024 | markets.businessinsider.comBuy Rating on Edwards Lifesciences Amid Expanding TAVR Market and Positive SMART Trial OutlookMarch 11, 2024 | businesswire.comLarge, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVRMarch 10, 2024 | finance.yahoo.comEW Aug 2024 97.500 callMarch 9, 2024 | finance.yahoo.comTMO Mar 2024 572.500 callMarch 7, 2024 | realmoney.thestreet.comBofA gets more bullish on Edwards Lifesciences, upgrades sharesMarch 7, 2024 | realmoney.thestreet.comEdwards Lifesciences upgraded to Buy at BofA after 'bullish' management meetingsMarch 7, 2024 | finance.yahoo.comEW Jun 2024 65.000 callMarch 7, 2024 | msn.comBofA upgrades Edwards to buy, says double-digit growth is backMarch 6, 2024 | wsj.comEdwards Lifesciences Corp.March 4, 2024 | markets.businessinsider.comBuy Rating on Edwards Lifesciences Amidst Strong TAVR Business and Promising TMTT ExpansionFebruary 29, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - EWFebruary 24, 2024 | msn.comEdwards Lifesciences (EW) Price Target Increased by 15.65% to 93.15See More Headlines Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/06/2024Today3/28/2024Next Earnings (Estimated)4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees19,800Year Founded1958Price Target and Rating Average Stock Price Target$88.80 High Stock Price Target$107.00 Low Stock Price Target$57.00 Potential Upside/Downside-7.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)$2.30 Trailing P/E Ratio41.42 Forward P/E Ratio34.51 P/E Growth4.63Net Income$1.40 billion Net Margins23.35% Pretax Margin26.61% Return on Equity23.56% Return on Assets16.81% Debt Debt-to-Equity Ratio0.09 Current Ratio3.38 Quick Ratio2.40 Sales & Book Value Annual Sales$6.00 billion Price / Sales9.54 Cash Flow$2.82 per share Price / Cash Flow33.81 Book Value$11.08 per share Price / Book8.60Miscellaneous Outstanding Shares601,300,000Free Float593,543,000Market Cap$57.28 billion OptionableOptionable Beta1.05 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Bernard J. Zovighian (Age 56)CEO & Director Comp: $1.04MMr. Scott B. Ullem (Age 57)Corporate VP & CFO Comp: $1.09MMr. Larry L. Wood (Age 58)Corporate VP and Group President of TAVR & Surgical Structural Heart Comp: $1.1MMr. Jean-Luc Lemercier (Age 67)Corporate Vice President of Japan, Asia Pacific & Greater China Comp: $1.24MDr. Todd J. Brinton FACCM.D., Corporate VP of Advanced Technology & Chief Scientific OfficerMark WilterdingVice President of Investor RelationsMr. Arnold A. Pinkston (Age 65)Corporate VP & General Counsel Mr. Dirksen J. LehmanCorporate Vice President of Public AffairsMr. Donald E. Bobo Jr. (Age 62)Corporate Vice President of Strategy & Corporate Development Comp: $1.26MMs. Christine Z. McCauley (Age 59)Corporate Vice President of Human Resources More ExecutivesKey CompetitorsSTERISNYSE:STEIntuitive SurgicalNASDAQ:ISRGZimmer BiometNYSE:ZBHAlign TechnologyNASDAQ:ALGNDexComNASDAQ:DXCMView All CompetitorsInsiders & InstitutionsNewbridge Financial Services Group Inc.Sold 136 shares on 3/28/2024Ownership: 0.000%Nomura Holdings Inc.Bought 12,240 shares on 3/27/2024Ownership: 0.002%HighPoint Advisor Group LLCBought 12,526 shares on 3/26/2024Ownership: 0.002%PNC Financial Services Group Inc.Sold 44,738 shares on 3/22/2024Ownership: 0.113%Accent Capital Management LLCBought 4,040 shares on 3/19/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Edwards Lifesciences was last updated on Tuesday, March 26, 2024 at 11:11 PM. Pros Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.: Edwards Lifesciences Co. has a strong market capitalization of $55.51 billion, indicating stability and potential for growth. The company offers innovative transcatheter heart valve replacement products under the Edwards SAPIEN family, which are in high demand due to their minimally invasive nature and effectiveness. Recent institutional investments in Edwards Lifesciences, such as Nordea Investment Management AB's significant stake increase, reflect confidence in the company's future performance. Edwards Lifesciences Co. has a diverse product portfolio, including critical care monitoring systems like FloTrac and HemoSphere, catering to a wide range of healthcare needs. The stock price of Edwards Lifesciences Co. has shown resilience, with a 52-week high of $95.27, indicating positive investor sentiment and potential for returns. Cons Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons: Edwards Lifesciences Co. operates in the highly competitive healthcare equipment industry, facing challenges from other established players and potential market saturation. The company's price-to-earnings ratio of 40.13 and price-to-earnings-growth ratio of 4.61 may indicate a relatively high valuation, potentially limiting short-term gains for investors. While recent institutional investments show confidence, they also raise concerns about potential market fluctuations impacting the stock price of Edwards Lifesciences Co. Investors should consider the company's debt-to-equity ratio of 0.09, as higher debt levels can pose risks during economic downturns or challenging market conditions. Market volatility and regulatory changes in the healthcare sector could impact the performance of Edwards Lifesciences Co., leading to uncertainties for investors. EW Stock Analysis - Frequently Asked Questions Should I buy or sell Edwards Lifesciences stock right now? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EW shares. View EW analyst ratings or view top-rated stocks. What is Edwards Lifesciences' stock price target for 2024? 17 equities research analysts have issued 12 month price objectives for Edwards Lifesciences' stock. Their EW share price targets range from $57.00 to $107.00. On average, they predict the company's share price to reach $88.80 in the next twelve months. This suggests that the stock has a possible downside of 7.1%. View analysts price targets for EW or view top-rated stocks among Wall Street analysts. How have EW shares performed in 2024? Edwards Lifesciences' stock was trading at $76.25 at the start of the year. Since then, EW stock has increased by 25.3% and is now trading at $95.56. View the best growth stocks for 2024 here. Are investors shorting Edwards Lifesciences? Edwards Lifesciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 10,450,000 shares, an increase of 23.8% from the February 29th total of 8,440,000 shares. Based on an average daily volume of 3,940,000 shares, the days-to-cover ratio is currently 2.7 days. Approximately 1.8% of the shares of the stock are sold short. View Edwards Lifesciences' Short Interest. When is Edwards Lifesciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our EW earnings forecast. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) released its quarterly earnings data on Tuesday, February, 6th. The medical research company reported $0.64 EPS for the quarter, meeting analysts' consensus estimates of $0.64. The medical research company earned $1.53 billion during the quarter, compared to analysts' expectations of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a trailing twelve-month return on equity of 23.56%. The firm's quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.64 earnings per share. Read the conference call transcript. What ETFs hold Edwards Lifesciences' stock? ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Neuberger Berman Disrupters ETF (NBDS), Global X Aging Population ETF (AGNG), Fidelity Disruptive Medicine ETF (FMED), First Trust Indxx Medical Devices ETF (MDEV), ETC 6 Meridian Quality Growth ETF (SXQG), BNY Mellon Sustainable US Equity ETF (BKUS) and Goldman Sachs Future Health Care Equity ETF (GDOC). When did Edwards Lifesciences' stock split? Shares of Edwards Lifesciences split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were payable to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What guidance has Edwards Lifesciences issued on next quarter's earnings? Edwards Lifesciences updated its first quarter 2024 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of 0.620-0.660 for the period, compared to the consensus earnings per share estimate of 0.660. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion. What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO? 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS). Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.71%), Vanguard Group Inc. (8.63%), Brown Advisory Inc. (3.00%), Wellington Management Group LLP (2.80%), Capital International Investors (1.49%) and Norges Bank (1.40%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daniel J Lippis, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.Read More This page (NYSE:EW) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.